Evaluation of hematologic factors and bilirubin following exchange transfusion in neonatal hyperbilirubinemia

Transfus Apher Sci. 2022 Oct;61(5):103451. doi: 10.1016/j.transci.2022.103451. Epub 2022 Apr 26.

Abstract

Introduction: Exchange transfusion (ECT) is one of effective treatments for rapid reduction of the bilirubin serum levels. The main purpose of this study was to offer greater insights into the effects of ECT on the hematologic factors and bilirubin in neonatal hyperbilirubinemia.

Methods: This cross-sectional study was performed on 380 neonates over 35 gestational weeks, and 2-14 days old with a bilirubin of above 17 mg/dl who had undergone ECT at Ghaem Hospital of Mashhad in Iran from 2011 to 2021. Blood samples were examined before, immediately after, 6 h and 60 h after ECT for complete blood cell count (CBC), platelet count and bilirubin serum level analysis.

Results: In this study, the mean age of neonates was 5.21 ± 3.55 days with a mean birth weight of 2810 ± 710 gr. The mean platelet count (PLT), white blood cell (WBC) and the serum level of bilirubin were estimated at 260,000/mm2, 12,400/mm2, 23 mg/dl before ECT and 97,000/mm2, 7370//mm2 and 12.6 mg/dl immediately after ECT, respectively (P-value <0.001).

Conclusion: The results indicated that the mean serum levels of bilirubin, platelets, and leukocytes dropped to 55%, 30%, and 60% of their baseline levels before ECT, respectively, but they all spiked after ECT.

Keywords: Bilirubin; Exchange transfusion; Hematologic factors; Neonatal hyperbilirubinemia; Platelet count; White blood cell.

MeSH terms

  • Bilirubin*
  • Cross-Sectional Studies
  • Exchange Transfusion, Whole Blood / methods
  • Humans
  • Hyperbilirubinemia, Neonatal* / therapy
  • Infant, Newborn
  • Treatment Outcome

Substances

  • Bilirubin